Search results
Results From The WOW.Com Content Network
Secukinumab. Secukinumab, sold under the brand name Cosentyx among others, is a human IgG1κ monoclonal antibody used for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. [4][5][6] It binds to the protein interleukin (IL)-17A and is marketed by Novartis. [4][5][6]
List of largest biomedical companies by revenue. The following is a list of independent pharmaceutical, biotechnology and medical companies listed on a stock exchange (as indicated) that have generated a revenue of at least US$ 10 billion, ranked by their revenue in the respective financial year. It does not include biotechnology companies that ...
Bimagrumab (BYM338) is a human monoclonal antibody developed by Novartis to treat pathological muscle loss and weakness. It binds to and inhibits activin receptor type-2B. [1] Bimagrumab must be administered intravenously at a hospital or clinic. The medication has a long half life and is administered once a month. [2]
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022. [4][5] Novartis manufactures the drugs clozapine (Clozaril), diclofenac (Voltaren; sold to ...
Fiona Hamilton Marshall FRS FMedSci is a British pharmacologist, biotech-founder and President of Biomedical Research at Novartis. [3][2][4] She founded and previously served as Chief Scientific Officer at Heptares Therapeutics, [2] which was acquired by the Japanese biopharmaceutical company Sosei, where she served as Vice President. [1]
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
Advanced Accelerator Applications (AAA or Adacap) is a France-based pharmaceutical group, specialized in the field of nuclear medicine. [1] The group operates in all three segments of nuclear medicine (PET, SPECT and therapy) to diagnose and treat serious conditions in the fields of oncology, neurology, cardiology, infectious and inflammatory diseases.
Sacubitril/valsartan, sold under the brand name Entresto among others, is a fixed-dose combination medication for use in heart failure. It consists of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker valsartan. The combination is sometimes described as an "angiotensin receptor-neprilysin inhibitor" (ARNi). [9]